PDCD1 and esophageal squamous cell carcinoma: Since the PD‐1 inhibitor combined with anti‐angiogenesis or chemotherapy was the main second‐line combination strategy in immunotherapy‐naive ESCC patients, the current study attempted to explore the benefits of the second‐line PD‐1 inhibitor combined with anti‐angiogenesis as compared with chemotherapy.